|Day Low/High||0.74 / 0.80|
|52 Wk Low/High||0.74 / 1.65|
Elimination of liquidity covenants frees working capital to fuel company growth
20 electronic posters available for review as well
Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities
ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy
Signs license agreement with pSivida for posterior uveitis in Europe, the Middle East and Africa
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.